Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain-Guided therapy shows promise for Late-Life depression

NCT ID NCT04543773

Symptom relief Sponsor: University of New Mexico Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study tests a new way to deliver an FDA-approved treatment called TMS (transcranial magnetic stimulation) for depression in adults aged 60 to 79. Researchers use fMRI brain scans to personalize the treatment target. The goal is to improve depression symptoms and brain connectivity. 24 participants are enrolled in this early-phase study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant must be at least 60 years of age (all genders, races, and ethnicities), and less than or equal to 79 years of age. 2. Participant must have a diagnosis of major depressive disorder without psychosis for the past 6 months, as diagnosed by a board-certified psychiatrist 3. Must show evidence of being in a current major depressive episode, as indicated by score on QIDS-C of 10 or higher. 4. Participant must not have any conditions listed in the exclusion criteria 5. Participant must be fluent in English Exclusion Criteria: 1. Current diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, or any other psychotic disorder 2. Substance use disorder, abuse or dependence, with active use within the last 3 months 3. Legal or mental incompetency, or inability to consent to study 4. Unstable medical illness, or hospitalization within 3 weeks of study entry 5. Current diagnosis of a neurological disorder or neurocognitive disorder 6. Prior neurosurgical procedure 7. History of seizure 8. History of ECT treatment within the past three months 9. History of any previous TMS treatment 10. Any contraindication to obtaining magnetic resonance imaging safely 11. Pregnant women 12. Inability to complete the protocol, namely, inability to independently attend all study visits and TMS sessions on time.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder

Contacts and locations

Locations

  • University of New Mexico HSC

    Albuquerque, New Mexico, 87106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.